Last reviewed · How we verify
Intravenous Lignocain
Intravenous Lignocain is a Local anesthetic Small molecule drug developed by Shaheed Mohtarma Benazir Bhutto Institue of Trauma. It is currently in Phase 2 development for Local anesthesia.
Blocks sodium channels
Blocks sodium channels Used for Local anesthesia.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Intravenous Lignocain |
|---|---|
| Sponsor | Shaheed Mohtarma Benazir Bhutto Institue of Trauma |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Lignocaine is a local anesthetic that works by blocking the sodium channels in the neuronal membrane, preventing the initiation and transmission of nerve impulses.
Approved indications
- Local anesthesia
Common side effects
- Hypotension
- Tachycardia
- Nausea
- Vomiting
- Allergic reactions
Key clinical trials
- Comparison of IV Lignocain and IV Dexmedetomidine for Attenuation of Laryngoscopic Stress Response to Direct Laryngoscopy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Lignocain CI brief — competitive landscape report
- Intravenous Lignocain updates RSS · CI watch RSS
- Shaheed Mohtarma Benazir Bhutto Institue of Trauma portfolio CI
Frequently asked questions about Intravenous Lignocain
What is Intravenous Lignocain?
How does Intravenous Lignocain work?
What is Intravenous Lignocain used for?
Who makes Intravenous Lignocain?
What drug class is Intravenous Lignocain in?
What development phase is Intravenous Lignocain in?
What are the side effects of Intravenous Lignocain?
What does Intravenous Lignocain target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Shaheed Mohtarma Benazir Bhutto Institue of Trauma — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Local anesthesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing